2021
DOI: 10.1080/02770903.2021.1900864
|View full text |Cite
|
Sign up to set email alerts
|

Fluticasone/formoterol compared with other ICS/LABAs in asthma: a systematic review

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(2 citation statements)
references
References 38 publications
0
2
0
Order By: Relevance
“…A combination of inhaled steroids (ICSs) with long-acting beta two agonists (LABAs) has become more or less the standard of care in asthma. Many ICS–LABA combinations are commercially available, although recent reviews and systematic reviews[ 6 , 7 ] have highlighted the advantages of formoterol-fluticasone therapy. Patients with severe asthma who remain uncontrolled despite a high dose of ICS–LABA merit therapy with biological agents.…”
Section: Introductionmentioning
confidence: 99%
“…A combination of inhaled steroids (ICSs) with long-acting beta two agonists (LABAs) has become more or less the standard of care in asthma. Many ICS–LABA combinations are commercially available, although recent reviews and systematic reviews[ 6 , 7 ] have highlighted the advantages of formoterol-fluticasone therapy. Patients with severe asthma who remain uncontrolled despite a high dose of ICS–LABA merit therapy with biological agents.…”
Section: Introductionmentioning
confidence: 99%
“…Allergic asthma is a chronic heterogeneous disease, affecting about 300 million people worldwide, and the burden of this disease is increasing in many countries [1]. It is characterized by eosinophilic inflammation, mucus hyper-production, airway hyper-responsiveness (AHR) and even airway remodeling [2].…”
Section: Introductionmentioning
confidence: 99%